Therapeutic Area
Drug: Indication (Target)
Preclinical
Phase I
Phase II
Phase III
Anticipated Milestones
Anticipated Milestones
Report Top-Line CLASSIC Trial Results in mid 2016

Initiate Phase III in AAV in 2H 2016

Drug: Indication (Target)
Pre
PI
PII
PIII
Anticipated Milestones

Prepare for EOP2 Meeting

Anticipated Milestones
Report Early Results from Pancreatic Cancer Trial H1 2016 and initial PFS results in 2H 2016
Drug: Indication (Target)
Pre
PI
PII
PIII
CCX354: Rheumatoid Arthritis/Myeloma Bone Metastasis (CCR1)
Anticipated Milestones

Explore Partnering Options to Advance Program in IBD

CCR1 CCX354 Completed Phase IIa

Progress in TH17 Disease

* also known as CCX282 or Traficet-EN.